Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
Incyte reported Q2 2026 total revenue of $1.67 billion, up 38% year-over-year, with total net sales rising 40% to $1.49 billion driven by broad-based product growth. Jakafi sales increased 7% to $817 million, while Opzelura sales jumped 173% to $450 million including a one-time $246 million benefit from a CMS settlement; Hematology and Oncology portfolio sales climbed 69% to $222 million.
Key figures
- Eps
- 2.81
- Revenue
- 1674000000
- Guidance
- FY26 total net sales $5.13B - $5.26B (raised from $4.77B - $4.94B); Total GAAP R&D and SG&A operating expenses $4.92B - $5.00B
- Revenue Yoy
- 38%
- Jakafi sales
- 817000000
- Cash position
- 4500000000
- Hem onc sales
- 222000000
- Opzelura sales
- 450000000
- Iprd expense q3
- 1270000000
- Total net sales
- 1490000000
- Vega deal value
- 1250000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.